Vertex wins FDA label expansion for Alyftrek cystic fibrosis treatment in ages 6+

Reuters04-01
Vertex wins FDA label expansion for Alyftrek cystic fibrosis treatment in ages 6+
  • US FDA cleared expanded labels for Vertex cystic fibrosis drugs ALYFTREK and TRIKAFTA.
  • ALYFTREK now covers patients age 6+ with CFTR variants responsive to clinical or in vitro data or that produce CFTR protein.
  • TRIKAFTA indication now includes patients age 2+.
  • Vertex said label changes lift CFTR modulator eligibility to about 95% of US cystic fibrosis patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260401690804) on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment